Berliner Abendpost - Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024

NYSE - LSE

CMSC	0.18%	21.99	$
CMSD	-0.14%	22.15	$
BCC	0.59%	75.93	$
JRI	0.46%	13	$
RELX	1.72%	31.93	$
NGG	3.22%	82.85	$
RIO	1.13%	94.42	$
RBGPF	3.73%	68.15	$
RYCEF	2.74%	19.68	$
VOD	1.06%	13.15	$
BCE	1.87%	21.42	$
AZN	5.79%	195.15	$
GSK	4.4%	53.66	$
BTI	1.96%	61.77	$
BP	3.34%	37.4	$

Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024

BOULEVARD 22.11.2024

Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024

Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference taking place December 3-5, 2024 in Coral Gables, Florida. The Company will also participate in one-on-one meetings.

Text size:

7th Annual Evercore ISI HealthCONx Conference - December 3-5, 2024

Format: Fireside Chat
Day/Time: Tuesday, December 3 at 8:45 A.M. ET
Webcast: https://wsw.com/webcast/evercore44/ptgx/2402505

If you are interested in meeting with the Protagonist team during the conference, please reach out to your Evercore representative.

A replay of the fireside will be available on the Company's Investor Relations Events and Presentations webpage for one year following the event.

About Protagonist
Protagonist Therapeutics is a late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA potentially in 2025. Icotrokinra (JNJ-2113, formerly PN-235), is the first targeted oral peptide designed to selectively block the IL-23 receptor,which underpins the inflammatory response in moderate-to-severe plaque PsO and other IL-23-mediated diseases. Icotrokinra binds to the IL-23 receptor with single-digit picomolar affinity and demonstrated potent, selective inhibition of IL-23 signaling in human T cells. Icotrokinra is licensed to Johnson & Johnson and is currently in Phase 3 development for psoriasis and is nearing completion of Phase 2b development for ulcerative colitis. Following icotrokinra's joint discovery by Protagonist and Johnson & Johnson scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for development of icotrokinra through Phase 1, with Johnson & Johnson assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera. Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered into in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of pre-clinical stage oral drug discovery programs addressing clinically and commercially validated targets, including IL-17, hepcidin mimetic, and anti-obesity programs.

More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at www.protagonist-inc.com.

Contact Information
Corey Davis Ph.D.
Investor Relations Contact - LifeSci Advisors
[email protected]
+1 212 915 2577

Virginia Amann
Media Relations Contact - ENTENTE Network of Companies
[email protected]
+1 833 500 0061 ext 1

SOURCE: Protagonist Therapeutics

G.Schulz--BlnAP

Featured

Man dies after setting self ablaze outside UN in New York: police

A man died after setting himself on fire outside the UN's headquarters in New York on Thursday, police said, with activists and reports identifying him as a pro-Tibet campaigner.

Death toll hits 10 in Thai monk procession crash

The number of monks killed has risen to 10 after an 11-year-old boy drove a pickup truck into a Buddhist procession in Thailand, officials said Friday.

Tajik names for Tajik babies: strict rules leave parents stranded

After giving birth, Shakhnoza Nazarova thought registering her daughter's name would be a mere formality. Instead, her chosen name was rejected -- deemed not Tajik enough by authorities of the Central Asian country.

Macabre night in La Guaira, Venezuela's earthquake epicenter

A macabre darkness, the glare of spotlights, the droning of generators and jackhammers, and often the stench of decomposing corpses: eight days after the double earthquake in Venezuela, nighttime in La Guaira, once a festive seaside resort, has transformed into a grim scene of survival and despair.